Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination product containing **hyaluronic acid** (a glycosaminoglycan with powerful moisturizing and film-forming properties) and **Icelandic moss** extract (*Cetraria islandica*, a lichen known for its traditional use in soothing and protecting mucous membranes). The combination is used primarily in topical formulations such as pastilles or gels aimed at relieving dryness, irritation, and soreness of the throat and mouth mucosa. Hyaluronic acid forms a hydrating protective film, while Icelandic moss provides soothing, demulcent, and mild anti-inflammatory effects. The combination is intended for symptomatic relief of throat irritation, hoarseness, and related mucosal discomfort, especially in the context of colds or voice strain[2][5][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronic acid + icelandic moss.